Ocean Biomedical Inc. (NASDAQ: OCEA). At a recent gathering of the Legorreta Cancer Center in Providence, Dr. Jack A. Elias, Scientific Co-Founder of Ocean Biomedical, gave an overview of his previously published findings that may have implications for tumor suppression across numerous cancer pathways.
Dr. Elias’ presentation concentrated on the ground-breaking work his group has done to comprehend the onset and progression of lung cancer, particularly the function of chitinase 3-like-1 (CHI3L1).
He also discussed the specifics of his groundbreaking therapeutic findings, which demonstrate the effectiveness of monospecific and bispecific antibodies against CHI3L1 and PD-1 as treatments for glioblastoma multiforme and non-small cell lung cancer.
These antibody therapeutic discoveries are presently being moved by Ocean Biomedical toward Phase 1 clinical trials.
“Immunotherapy is the future of cancer treatment,” said Suren Ajjarapu, a director at Ocean Biomedical, “and we are pleased to be working with Dr. Elias to advance the development of his cancer treatments, as well as his fibrosis treatments, and our global malaria program. For the benefit of long-term shareholder value and the continued advancement of medical science, we look forward to offering all of these therapies to patients as Ocean Biomedical develops.
Ocean Biomedical, Inc. is a biopharmaceutical firm with headquarters in Providence, Rhode Island. Its cutting-edge business strategy expedites the development and commercialization of scientifically compelling assets from research universities and hospitals. Ocean Biomedical has the resources and know-how to quickly take fresh therapeutic candidates from the lab to the clinic and beyond. In the areas of lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria, Ocean Biomedical is currently working to advance five promising discoveries that have the potential to make a significant difference in people’s lives. For the benefit of those who need it most, the Ocean Biomedical team is tackling some of the most difficult problems in the world.
